GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » EKIMAS Corp (OTCPK:ASNB) » Definitions » Research & Development

EKIMAS (EKIMAS) Research & Development : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 1996. Start your Free Trial

What is EKIMAS Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. EKIMAS's Research & Development for the three months ended in Dec. 2022 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

EKIMAS Research & Development Historical Data

The historical data trend for EKIMAS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EKIMAS Research & Development Chart

EKIMAS Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.35 0.31 - -

EKIMAS Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

EKIMAS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EKIMAS  (OTCPK:ASNB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

EKIMAS Research & Development Related Terms

Thank you for viewing the detailed overview of EKIMAS's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

EKIMAS (EKIMAS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » EKIMAS Corp (OTCPK:ASNB) » Definitions » Research & Development
Comparable Companies
HGYN CIIT WBQNL GPLL MVCO IWSH PCMC NLSC EEGI ADAD CVII SVMB BOM:543385 SCRM XAMS:PACE EOCW AAC CCVI ALCC GHIX
Traded in Other Exchanges
N/A
Address
3651 Lindell Road, Suite D565, Las Vegas, NV, USA, 89103
Website
http://www.advbiomaterials.com
EKIMAS Corp is a shell company.
Executives
Partners Aps Gk 10 percent owner MESTERLODDEN 3B, GENTOFTE G7 2820
Henrik Oerbekker 10 percent owner 94, RUE DES AUBEPINES, L-1145, LUXEMBOURG N4 2449
Henrik Rouf 10 percent owner 468 N. CAMDEN DR., SUITE 350, BEVERLY HILLS CA 90210
Khristine L Carroll officer: EVP Commercial Operations 229 ANDOVER STREET, WILMINGTON MA 01887
Michael F Adams director, officer: Chief Executive Officer 78 E OLYMPIA AVE, C/O CARDIO TECH INTERNATIONAL INC, WOBURN MA 01810-2057
David Crispino Volpe officer: Chief Financial Officer 235 STONEBRIDGE DRIVE, NASHUA NH 03063
Michael L Barretti director 78 E OLYMPIA AVE, C/O CARDIO TECH INTERNATIONAL INC, WOBURN MA 01810-2057
Oneill William J Jr director 4000 HOLLYWOOD BLVD STE 650N, HOLLYWOOD FL 33021
Mark R Tauscher director
Eric G Walters officer: Vice President and CFO C/O MFIC CORP, 30 OSSIPEE RD., NEWTON MA 02464
Andrew Martin Reed officer: VP of Science and Technology 12106 WEST 75TH LANE, ARVADA CO 80005
Philip Alan Beck other: General manager 1230 CREEKSIDE CROSSING, STILLWATER MN 55082
Jeremiah E Dorsey director P.O. BOX 910, QUECHEE VT 05059
Leslie M Taeger officer: CFO
Douglas E Whittaker officer: President Gish Biomedical